BREAKING NEWS: Luminate Medical, a Galway-based medtech innovator, has just raised $21 million in a significant funding round aimed at expanding its at-home cancer treatment offerings. This funding surge brings the company’s total capital to over $50 million and comes hand-in-hand with the announcement of 130 new jobs within the organization over the next three years.
The funding round was co-led by Lachy Groom and ARTIS Ventures, with participation from Western Alliance Life Sciences, as well as existing investors including 8VC, Y Combinator, Atlantic Bridge, Faber, SciFounders, and Elkstone. Amid rising interest from US healthcare organizations, Luminate is set to enhance its innovative Lotus programme, which focuses on delivering cancer care directly to patients’ homes.
Luminate Medical’s latest initiative comes as a response to the substantial demand for efficient cancer treatment methods. Patients undergoing chemotherapy typically spend one to three days in a hospital, making at-home treatments a game changer. The company plans to roll out access to home cancer care at 40 partner oncology clinics before launching its patient-led home infusion technology later this year.
In a statement, CEO and co-founder Aaron Hannon emphasized the importance of making cancer treatment more accessible. “Cancer doesn’t need to mean life-changing financial, time, or physical burdens on patients. Our technology empowers providers while significantly reducing costs for both the healthcare system and the patients themselves,” Hannon stated.
Luminate Medical’s plans also include launching clinical studies of its Lotus auto-injector and monitoring technologies in the first half of 2026. These advancements will enable patients to self-administer anti-cancer therapies in the comfort of their own homes.
As part of its growth strategy, Luminate is actively recruiting for a variety of roles, including software developers, electronics experts, clinical researchers, mechanical designers, and oncology nurses. The company aims to build a robust workforce both in Galway and across the US.
Originally founded in 2018 at the University of Galway by Hannon, Dr. Barbara Oliveira, and Professor Martin O’Halloran, Luminate Medical has quickly positioned itself as a leader in the at-home cancer care sector. In April 2022, the organization received €6.4 million through the DTIF programme to develop a smart system for at-home anti-cancer treatment.
As the healthcare landscape continues to evolve, Luminate Medical’s rapid expansion and innovative solutions stand to redefine cancer care, making it more patient-centric and accessible.
Stay tuned for further updates on Luminate Medical’s groundbreaking initiatives and the future of cancer treatment.
